Literature DB >> 33856403

Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung Cancer.

Lova Sun1, Miles Hsu1, Roger B Cohen1, Corey J Langer1, Ronac Mamtani1, Charu Aggarwal1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33856403      PMCID： PMC8050787          DOI： 10.1001/jamaoncol.2021.0546

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   33.006


× No keyword cloud information.
  21 in total

1.  Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study.

Authors:  Tae Hata; Chikara Sakaguchi; Keita Hirano; Hiroshi Kobe; Masaki Ishida; Takayuki Nakano; Yusuke Tachibana; Nobuyo Tamiya; Shinsuke Shiotsu; Takayuki Takeda; Tadaaki Yamada; Toshihide Yokoyama; Michiko Tsuchiya; Yukio Nagasaka
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-23       Impact factor: 4.553

2.  Systematic pan-cancer analysis of mutation-treatment interactions using large real-world clinicogenomics data.

Authors:  Shemra Rizzo; Sarah Waliany; Marius Rene Garmhausen; Navdeep Pal; Ruishan Liu; Zhi Huang; Nayan Chaudhary; Lisa Wang; Chris Harbron; Joel Neal; Ryan Copping; James Zou
Journal:  Nat Med       Date:  2022-06-30       Impact factor: 87.241

Review 3.  The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target-a narrative review.

Authors:  Alessia Spagnuolo; Paolo Maione; Cesare Gridelli
Journal:  Transl Lung Cancer Res       Date:  2022-06

4.  Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A.

Authors:  Karen L Reckamp; Mary W Redman; Konstantin H Dragnev; Katherine Minichiello; Liza C Villaruz; Bryan Faller; Tareq Al Baghdadi; Susan Hines; Leah Everhart; Louise Highleyman; Vassiliki Papadimitrakopoulou; Saiama N Waqar; Jyoti D Patel; Jhanelle E Gray; David R Gandara; Karen Kelly; Roy S Herbst
Journal:  J Clin Oncol       Date:  2022-06-03       Impact factor: 50.717

5.  Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1.

Authors:  Loïck Galland; Anne Laure Le Page; Julie Lecuelle; Frederic Bibeau; Youssef Oulkhouir; Valentin Derangère; Caroline Truntzer; François Ghiringhelli
Journal:  Oncoimmunology       Date:  2021-08-02       Impact factor: 8.110

Review 6.  Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants.

Authors:  Marco H Hofmann; Daniel Gerlach; Sandra Misale; Mark Petronczki; Norbert Kraut
Journal:  Cancer Discov       Date:  2022-04-01       Impact factor: 38.272

Review 7.  The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures.

Authors:  Miriam Grazia Ferrara; Alessio Stefani; Sara Pilotto; Carmine Carbone; Emanuele Vita; Mariantonietta Di Salvatore; Ettore D'Argento; Ileana Sparagna; Federico Monaca; Giustina Valente; Antonio Vitale; Geny Piro; Lorenzo Belluomini; Michele Milella; Giampaolo Tortora; Emilio Bria
Journal:  Front Oncol       Date:  2021-12-23       Impact factor: 6.244

Review 8.  Targeting KRAS in Non-Small Cell Lung Cancer.

Authors:  Elena Corral de la Fuente; Maria Eugenia Olmedo Garcia; Ana Gomez Rueda; Yolanda Lage; Pilar Garrido
Journal:  Front Oncol       Date:  2022-01-10       Impact factor: 6.244

9.  Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases.

Authors:  Adam Lauko; Rupesh Kotecha; Addison Barnett; Hong Li; Vineeth Tatineni; Assad Ali; Pradnya Patil; Alireza M Mohammadi; Samuel T Chao; Erin S Murphy; Lilyana Angelov; John H Suh; Gene H Barnett; Nathan A Pennell; Manmeet S Ahluwalia
Journal:  Sci Rep       Date:  2021-09-13       Impact factor: 4.379

Review 10.  Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.

Authors:  Daolin Tang; Guido Kroemer; Rui Kang
Journal:  Mol Cancer       Date:  2021-10-04       Impact factor: 27.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.